CAS NO: | 50-35-1 |
规格: | ≥98% |
包装 | 价格(元) |
100mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
Molecular Weight (MW) | 258.23 |
---|---|
Formula | C13H10N2O4 |
CAS No. | 50-35-1 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 52 mg/mL (201.37 mM) |
Water:<1 mg/mL (slightly soluble or insoluble) | |
Ethanol: 2 mg/mL (7.74 mM) | |
Solubility (In vivo) | 30% PEG400+0.5% Tween80+5% Propylene glycol: 5 mg/mL |
Chemical Name | Chemical Name: 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione InChi Key: UEJJHQNACJXSKW-UHFFFAOYSA-N InChi Code: InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17) SMILES Code: O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O |
Synonyms | Brand names: Synovir; Thalomid (US); Foreign brand names: Contergan; Distaval; Kevadon; Neurosedyn; Pantosediv; Sedoval K17; Softenon Talimol; alphaphthalimidoglutarimide. Nphthaloylglutamimide; Nphthalylglutamic acid imide. |
In Vitro | Thalidomide must be metabolized by the liver to form an epoxide that may be the active teratogenic metabolite. Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when human monocytes are triggered with lipopolysaccharide and other agonists in culture. |
---|---|
In Vivo | Thalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status. Thalidomide (200 mg/kg, p.o.) combined with icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death. |
Animal model | C57BL/6 mice |
Formulation & Dosage | 100 mg/kg, p.o. |
References | [1] D Amato RJ, et al. Proc Natl Acad Sci U S A, 1994, 91(9), 4082-4085. ; Free Radic Biol Med. 2018 Dec;129:446-453. |